Preliminary analysis revealed a significantly higher frequency of multiple TP53 mutations in MMRd–p53abn tumours when compared with single‐classifier p53abn (i.e. lacking POLE mutation or MSI‐H) ECs (36.4% versus 2.7%, p < 0.001, Fisher's exact test). This evidence concerns the gene TP53 and neoplasm.